Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Refractory Solid Tumors 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Arsenic Trioxide × Other solid neoplasm × Clear all
NCT04869475 2021-05-13

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Ruijin Hospital

Phase 2 Unknown
20 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡